Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Dec;5(6):1069-1071.
doi: 10.1002/ehf2.12355. Epub 2018 Oct 9.

Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al

Felix J A Ramires  1 , Felipe Martinez  2 , Efraín A Gómez  3 , Caroline Demacq  4 , Claudio R Gimpelewicz  5 , Jean L Rouleau  6 , Scott D Solomon  7 , Karl Swedberg  8   9 , Michael R Zile  10 , Milton Packer  11 , John J V McMurray  12
Affiliations
Comment

Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al

Felix J A Ramires et al. ESC Heart Fail. 2018 Dec.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Bocchi EA, Rassi S, Guimaraes GV, Argentina C, Brazil SI. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Fail 2018; 5: 249‐256. - PMC - PubMed
    1. Krum H, McMurray JJ, Abraham WT, Dickstein K, Kober L, Desai AS, Solomon SD, Chiang Y, Gimpelewicz C, Reimund B, Ali MA, Tarnesby G, Massie BM, ATMOSPHERE Committees and Investigators . The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. Eur J Heart Fail 2015; 17: 1075–1083. - PubMed
    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM‐HF Investigators and Committees . Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004. - PubMed
    1. Shen L, Ramires F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, Abraham WT, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV. Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail 2017; 10: e004361. - PubMed
    1. Benziger CP, do Carmo GAL, Ribeiro ALP. Chagas cardiomyopathy: clinical presentation and management in the Americas. Cardiol Clin 2017; 35: 31–47. - PubMed

LinkOut - more resources